JANX vs. CADL
JANX (Janux Therapeutics, Inc.) and CADL (Candel Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, JANX returned 4.68%/yr vs 86.97%/yr for CADL. At a 0.19 correlation, their price movements are largely independent.
Performance
JANX vs. CADL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, JANX achieves a 3.91% return, which is significantly lower than CADL's 61.95% return.
JANX
- 1D
- 0.84%
- 1M
- -1.24%
- YTD
- 3.91%
- 6M
- 1.77%
- 1Y
- -39.24%
- 3Y*
- 4.68%
- 5Y*
- -9.18%
- 10Y*
- —
CADL
- 1D
- 10.11%
- 1M
- 14.52%
- YTD
- 61.95%
- 6M
- 54.04%
- 1Y
- 92.63%
- 3Y*
- 86.97%
- 5Y*
- —
- 10Y*
- —
JANX vs. CADL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
JANX Janux Therapeutics, Inc. | 3.91% | -74.22% | 398.97% | -18.53% | -33.25% | -30.55% |
CADL Candel Therapeutics, Inc. | 61.95% | -34.91% | 490.48% | -17.88% | -77.11% | -2.25% |
Correlation
The correlation between JANX and CADL is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.39 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Jul 27, 2021 | 0.19 |
Over the past year, JANX and CADL have become more correlated (0.39) than their long-term average of 0.19, meaning their price movements have been converging.
Fundamentals
JANX:
$898.63M
CADL:
$570.61M
JANX:
-$1.84
CADL:
-$0.97
JANX:
0.95
CADL:
4.13
JANX:
$21.61M
CADL:
$0.00
JANX:
$8.44M
CADL:
-$600.00K
JANX:
-$134.03M
CADL:
-$71.64M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
JANX vs. CADL — Risk / Return Rank
JANX
CADL
JANX vs. CADL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and Candel Therapeutics, Inc. (CADL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JANX | CADL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.80 | ||
| Sortino ratioReturn per unit of downside risk | -2.31 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.25 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | -0.61 | 2.51 | -3.12 |
| Martin ratioReturn relative to average drawdown | -0.89 | 4.52 | -5.41 |
Loading charts...
Drawdowns
JANX vs. CADL - Drawdown Comparison
The maximum JANX drawdown since its inception was -83.14%, smaller than the maximum CADL drawdown of -94.33%. Use the drawdown chart below to compare losses from any high point for JANX and CADL.
Loading charts...
Drawdown Indicators
| JANX | CADL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.14% | -94.33% | +11.19% |
Max Drawdown (1Y)Largest decline over 1 year | -64.94% | -37.04% | -27.90% |
Max Drawdown (3Y)Largest decline over 3 years | -81.78% | -72.86% | -8.92% |
Max Drawdown (5Y)Largest decline over 5 years | -83.14% | — | — |
Current DrawdownCurrent decline from peak | -78.54% | -34.64% | -43.90% |
Average DrawdownAverage peak-to-trough decline | -52.75% | -62.57% | +9.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.34% | 20.57% | +23.77% |
Volatility
JANX vs. CADL - Volatility Comparison
The current volatility for Janux Therapeutics, Inc. (JANX) is 9.32%, while Candel Therapeutics, Inc. (CADL) has a volatility of 18.78%. This indicates that JANX experiences smaller price fluctuations and is considered to be less risky than CADL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| JANX | CADL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.32% | 18.78% | -9.46% |
Volatility (6M)Calculated over the trailing 6-month period | 29.29% | 52.74% | -23.45% |
Volatility (1Y)Calculated over the trailing 1-year period | 73.99% | 73.67% | +0.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 130.71% | 166.61% | -35.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 131.25% | 166.61% | -35.36% |
Dividends
JANX vs. CADL - Dividend Comparison
Neither JANX nor CADL has paid dividends to shareholders.
Financials
JANX vs. CADL - Financials Comparison
This section allows you to compare key financial metrics between Janux Therapeutics, Inc. and Candel Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
JANX and CADL have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CADL has higher volatility (18.78%) compared to JANX (9.32%). In terms of maximum drawdown, JANX dropped -83.14% vs CADL's -94.33%.
CADL currently has the higher Sharpe Ratio (1.27 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for JANX and CADL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer